Nitric oxide concentrations and cerebrospinal fluid parameters in an experimental animal model of Streptococcus pneumoniae meningitis

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 612-619

  Destache, Christopher J ^a   Pakiz, Catherine B ^a   Dash, Alekha K ^a   Larsen, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; CEFTRIAXONE; DEXAMETHASONE; GLUCOSE; LACTIC ACID; NITRIC OXIDE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BRAIN EDEMA; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DRUG BRAIN LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MENINGITIS; NONHUMAN; PATHOPHYSIOLOGY; PENICILLIN RESISTANCE; RABBIT; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CEFTRIAXONE; CELL COUNT; CEPHALOSPORINS; CEREBROSPINAL FLUID PROTEINS; DEXAMETHASONE; DRUG INTERACTIONS; GLUCOSE; LACTIC ACID; LEUKOCYTES; MENINGITIS, PNEUMOCOCCAL; MICRODIALYSIS; NITRIC OXIDE; RABBITS; STREPTOCOCCUS PNEUMONIAE;

EID: 0031981875     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992;30:279-88.
2. Baralt LJ, Lee SI, Schringer DL. Outcome of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993;12:389-94.
3. Tauber MG, Hackbarth CJ, Scott KG, et al. New cephalosporins, cefotaxime, cefprimizole, BMY 28142, and HP 810 in experimental pneumococcal meningitis in rabbits. Clin Infect Dis 1994;19:463-79.
4. Destache CJ, Pakiz CB, McConnell S, Cavalieri SJ. Effect of penicillin resistance on morbidity and mortality of hospitalized patients. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 29, 1997.
5. Friedland IR, Klugman KP. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992;339:405-8.
6. Moncada S. The L-arginine:nitric oxide pathway. Acta Physiol Scand 1992;145:201-27.
7. Kiechle FL, Malinski T. Nitric oxide. Biochemistry, pathophysiology, and detection. Am J Clin Pathol 1993;100: 567-75.
8. Perry VL, Young RSK, Aquila WJ, During MJ. Effect of experimental Escherichia coli meningitis on concentrations of excitatory and inhibitory amino acids in the rabbit brain: in vivo microdialysis study. Pediatr Res 1993;34:187-93.
9. Buster BL, Weintrob AC, Townsend GC, Scheld WM. The potential role of nitric oxide in the pathophysiology of experimental bacterial meningitis in rats. Infect Immunol 1995;63:3835-9.
10. Tunkel AR, Wispelwey B, Scheld WM. Bacterial meningitis: recent advances in pathophysiology and treatment. Ann Intern Med 1990;112:610-23.
11. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992;81:605-10.
12. Johansen MJ, Newman RA, Madden T. The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 1997;17:464-81.
13. Wong SL, van Belle K, Sawchuk RJ. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 1993;264:899-909.
14. Stahle L, Oberg B. Pharmacokinetics and distribution over the blood brain barrier of two acyclic guanosine analogs in rats, studies by microdialysis. Antimicrob Agents Chemother 1992;36:339-42.
15. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: update tables for NCCLS antimicrobial susceptibility testing standards M7-A2. NCCLS document M100-S4, 4th informational supplement, vol 12, no. 20. Villanova, PA: Author, 1992.
16. Wang Y, Wong SL, Sawchuk RJ. Comparison of in vitro and in vivo calibration of microdialysis probes using retrodialysis. Current Separations 1991;14:63.
17. Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974;6:437-41.
18. Sawyer CH, Everett JW, Green JD. The rabbit diencephalon in stereotaxic coordinates. J Comp Neurol 1954;101:801-24.
19. Jungbluth GL, Jusko WJ. Ion-paired reverse-phase high-performance liquid chromatography assay for determination of ceftriaxone in human plasma and urine. J Pharm Sci 1989;78:968-70.
20. Mustafa MM, Ramilo O, Mertsola J, et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type B meningitis. J Infect Dis 1989;160:818-25.
21. Schaad UB, Lips U, Gnehm HE, Blumberg A, Heinzer I, Wedgwood J. Dexamethasone therapy for bacterial meningitis in children. Swiss meningitis study group. Lancet 1993;342:457-61.
22. Guerra-Romero L, Tauber MG, Fournier MA, Tureen JH. Lactate and glucose concentrations in brain interstitial fluid, cerebrospinal fluid, and serum during experimental pneumococcal meningitis. J Infect Dis 1992;166:546-50.
23. World Precision Instruments, Inc. Iso-NO-200 owner's manual. Sarasota, FL: Author, February 1995.
24. Kornelisse RF, Hoekman K, Visser JJ, et al. The role of nitric oxide in bacterial meningitis in children. J Infect Dis 1996;174:120-6.
25. Haberl RL, Anneser F, Kodel U, Pfister H-W. Is nitric oxide involved as a mediator of cerebrovascular changes in the early phase of experimental pneumococcal meningitis? Neurol Res 1994;16:108-12.
26. Koedel U, Bernatowicz A, Paul R, Frei K, Fontana A, Pfister HW. Experimental pneumococcal meningitis: cerebrovascular alterations, brain edema, and meningeal inflammation are linked to the production of nitric oxide. Ann Neurol 1995;37:313-23.
27. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992;115:1249-73.
28. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
29. Hibbs JBJ, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94.
30. Cabellos C, Martinez-Lacasa J, Marios A, et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 1995;39:2158-60.
31. Paris MM, Hickey SM, Uscher MI, et al. Effect of dexamethasone on therapy of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38:1320-4.
32. Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993;37:1630-6.
33. Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis 1985;4:362-8.